Last reviewed · How we verify

Dinoprostone vaginal pessary

Università degli Studi di Brescia · FDA-approved active Small molecule

Dinoprostone is a prostaglandin F2α analog that binds to prostaglandin receptors on the uterus to stimulate myometrial contractions and promote cervical ripening and labor induction.

Dinoprostone is a prostaglandin F2α analog that binds to prostaglandin receptors on the uterus to stimulate myometrial contractions and promote cervical ripening and labor induction. Used for Cervical ripening and labor induction in pregnant women at or near term, Management of incomplete abortion or miscarriage.

At a glance

Generic nameDinoprostone vaginal pessary
Also known asPropess, Ferring, Milan, Italy
SponsorUniversità degli Studi di Brescia
Drug classProstaglandin F2α analog
TargetProstaglandin F (FP) receptor
ModalitySmall molecule
Therapeutic areaObstetrics
PhaseFDA-approved

Mechanism of action

Dinoprostone acts as a direct agonist of prostaglandin F (FP) receptors on uterine smooth muscle, triggering rhythmic contractions similar to those occurring during spontaneous labor. When administered as a vaginal pessary, it also promotes cervical softening and dilation by increasing local prostaglandin concentrations, facilitating cervical ripening in preparation for labor or delivery.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: